在克隆性瘤突变负担-高卵巢癌中的Gemogenovatucel-T优势
Robert L Coleman1, Rodney Rocconi2, Bradley J Monk3
1Texas Oncology, Shenandoah, TX.
JCO precision oncology
|January 14, 2026
概括
用gemogenovatucel-T进行维护疗法显著改善了卵巢癌患者的整体存活率,这些患者具有高克隆瘤突变负担和同源的复合性瘤. 这种有针对性的方法为晚期卵巢癌治疗提供了新的希望.
科学领域:
- 在瘤学瘤学.
- 基因组学就是基因组学.
- 临床试验 临床试验
背景情况:
- 对于晚期卵巢癌的标准前线治疗方法,包括贝瓦齐祖马布,PARP抑制剂和PD-1/PD-L1抑制剂,并没有改善同类重组能力 (HRP) 瘤患者的整体存活率.
- 识别与改善结果相关的特定突变特征对于开发更有效的疗法至关重要.
研究的目的:
- 确定与卵巢癌患者整体存活率 (OS) 优势相关的机械突变特征.
- 为了评估 gemogenovatucel-T 作为IIIb-IV期卵巢癌患者的维持疗法的疗效,这些患者具有同源重组能力 (HRP) 概况和高克隆瘤突变负担 (cTMB-H).
主要方法:
- 开发了一个全外因组测序生物信息管道来分析来自VITAL试验的91名患者.
- 假设患有IIIb-IV期卵巢癌,HRP概况和cTMB-H的患者可以从宝基诺瓦图塞尔-T维持疗法中受益.
- 总体存活率使用卡普兰-梅尔方法在随机,双盲,安慰剂控制的II期试验中进行了评估.
主要成果:
- 用gemogenovatucel-T治疗的cTMB-H/HRP卵巢癌患者的平均生存期为68个月,与安慰剂治疗的19个月相比 (危险比[HR],0.23;95% CI,0.06至0.83;P=.008).
- 在非HRP配置文件的cTMB-H患者中没有观察到OS优势 (HR,0.99;95% CI,0.39至2.47;P = .488).
- 在8.4年的随访期间,在gemogenovatucel-T组中没有观察到与治疗相关的3级毒性.
结论:
- 用gemogenovatucel-T进行维护疗法在新诊断的晚期卵巢癌的成年女性中显示出显著的整体生存优势.
- 在患有HRP状态和cTMB-H配置文件的患者中观察到这种益处,这些患者在手术和前线化疗后获得了完全反应.
- 这些发现支持基米诺瓦图塞尔-T作为卵巢癌患者的特定亚组的潜在向维护疗法.
相关概念视频
Cancer-Critical Genes I: Proto-oncogenes
11.1K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
11.1K
Cancer-Critical Genes II: Tumor Suppressor Genes
9.4K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
9.4K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Adaptive Mechanisms in Cancer Cells
7.0K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
7.0K
Cancers Originate from Somatic Mutations in a Single Cell
14.6K
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
14.6K


